Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial

Vaccine

Volumn 25, Issue 15, 2007, Pages 2930-2940

  Hermsen, Cornelus C ^a   Verhage, Danielle F ^a   Telgt, Denise S C ^a   Teelen, Karina ^a   Bousema, J Teun ^a   Roestenberg, Meta ^a   Bolad, Ahmed ^b   Berzins, Klavs ^b   Corradin, Giampietro ^c   Leroy, Odile ^d   Theisen, Michael ^d   Sauerwein, Robert W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

Clinical trial; GLURP; Immunization; Malaria; Montanide; Phase 1; Plasmodium falciparum

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; BACTERIAL PROTEIN; GLUTAMATE RICH PROTEIN [85-213]; IMMUNOGLOBULIN G1; MALARIA VACCINE; MONTANIDE ISA 720; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTHRALGIA; ARTICLE; ASTHMA; BLOOD SAMPLING; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FORMULATION; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FEVER; GROWTH INHIBITION; HEADACHE; HEART PALPITATION; HOARSENESS; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IN VITRO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALARIA; MALE; MICROBIAL GROWTH; MYALGIA; NAUSEA; NONHUMAN; NORMAL HUMAN; PALLOR; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SWEATING; SYNCOPE; URTICARIA;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; NEUTROPHILS; PEPTIDE FRAGMENTS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 33947107414     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.081     Document Type: Article

References (28)

1. Richie T.L., and Saul A. Progress and challenges for malaria vaccines. Nature 415 6872 (2002) 694-701
2. Sauerwein R.W. Immunology in medical practice. XXVII. Vaccines against malaria: new perspectives. Ned Tijdschr Geneeskd 144 2 (2000) 64-69
3. Borre M.B., Dziegiel M., Hogh B., et al. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol 49 1 (1991) 119-131
4. Dziegiel M., Rowe P., Bennett S., et al. Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children. Infect Immun 61 1 (1993) 103-108
5. Dodoo D., Theisen M., Kurtzhals J.A., et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 181 3 (2000) 1202-1205
6. Oeuvray C., Theisen M., Rogier C., Trape J.F., Jepsen S., and Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo Senegal. Infect Immun 68 5 (2000) 2617-2620
7. Theisen M., Dodoo D., Toure-Balde A., et al. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect Immun 69 9 (2001) 5223-5229
8. Soe S., Theisen M., Roussilhon C., Aye K.S., and Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72 1 (2004) 247-252
9. Lusingu J.P., Vestergaard L.S., Alifrangis M., et al. Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. Malar J 29 4 (2005) 48
10. Theisen M., Soe S., Oeuvray C., et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 66 1 (1998) 11-17
11. de Stricker K., Vuust J., Jepsen S., Oeuvray C., and Theisen M. Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol 111 1 (2000) 123-130
12. Price D.D., McGrath P.A., Rafii A., and Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17 1 (1983) 45-56
13. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., and Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172 6 (1990) 1633-1641
14. Bolad A., Nebie I., Esposito F., and Berzins K. The use of impregnated curtains does not affect antibody responses against Plasmodium falciparum and complexity of infecting parasite populations in children from Burkina Faso. Acta Trop 90 3 (2004) 237-247
15. Lambros C., and Vanderberg J.P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 65 3 (1979) 418-420
16. Malkin E.M., Durbin A.P., Diemert D.J., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 24 (2005) 3131-3138
17. Saul A., Lawrence G., Smillie A., et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17 23-24 (1999) 3145-3159
18. Walther M., Dunachie S., Keating S., et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine. ICC-1132 formulated in Seppic ISA 720. Vaccine 23 7 (2005) 857-864
19. Edelman R., Wasserman S.S., Kublin J.G., et al. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 21 3-4 (2002) 269-280
20. Keitel W.A., Kester K.E., Atmar R.L., et al. Phase I trial of two recombinant vaccines containing the 19 kDa carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18 5-6 (1999) 531-539
21. Migasena S., Heppner D.G., Kyle D.E., et al. SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand. Acta Trop 67 3 (1997) 215-227
22. Saul A., Lawrence G., Allworth A., et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23 23 (2005) 3076-3083
23. Nosten F., Luxemburger C., Kyle D.E., et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 348 9029 (1996) 701-707
24. Hogh B., Petersen E., Dziegiel M., et al. Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia. Am J Trop Med Hyg 46 3 (1992) 307-313
25. Theisen M., Soe S., Jessing S.G., et al. Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine 19 2-3 (2000) 204-212
26. Pombo D.J., Lawrence G., Hirunpetcharat C., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360 9333 (2002) 610-617
27. Bouharoun-Tayoun H., Oeuvray C., Lunel F., and Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182 2 (1995) 409-418
28. Garraud O., Mahanty S., and Perraut R. Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. Trends Immunol 24 1 (2003) 30-35